Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

A Feasibility Trial of LHRH Agonist Discontinuation in Elderly Prostate Cancer Patients

This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.

Inclusion Criteria:

• Prostate cancer with >3 years of LHRH agonist therapy.
• Age ≥70 years.
• ECOG performance status ≤2
• Baseline testosterone of < 20 ng/ml
• No prior chemotherapy or Lu-PSMA (unless survival predictions are favorable).
• Ability to understand and sign informed consent.

Exclusion Criteria:

• none